Published in Angiogenesis Weekly, August 30th, 2002
In this randomized clinical trial at Indiana University School of Medicine in Indianapolis, patients will self-inject a low dose or a high dose of Angiostatin under the skin twice daily. Concomitantly, Paclitaxel and carboplatin, considered standard chemotherapy for NSCLC, will be administered every 3 weeks via intravenous bolus administration for up to 18 weeks.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Angiogenesis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.